Nanexa AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NANEXA.ST research report →
Companywww.nanexa.com
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia.
- CEO
- David Westberg
- IPO
- 2015
- Employees
- 13
- HQ
- Uppsala, SE
Price Chart
Valuation
- Market Cap
- $561.70M
- P/E
- -37.78
- P/S
- 16.09
- P/B
- 4.88
- EV/EBITDA
- -1135.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 49.01%
- Op Margin
- -38.91%
- Net Margin
- -47.05%
- ROE
- -16.59%
- ROIC
- -10.53%
Growth & Income
- Revenue
- $36.15M · 48.39%
- Net Income
- $-11,388,000 · 54.27%
- EPS
- $-0.07 · 59.44%
- Op Income
- $-15,460,000
- FCF YoY
- 51.95%
Performance & Tape
- 52W High
- $5.00
- 52W Low
- $1.40
- 50D MA
- $3.71
- 200D MA
- $3.00
- Beta
- 1.86
- Avg Volume
- 573.05K
Get TickerSpark's AI analysis on NANEXA.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NANEXA.ST Coverage
We haven't published any research on NANEXA.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NANEXA.ST Report →